Focus: Perceptive is a UK-based medical imaging biotech specializing in optical coherence tomography (OCT) and vascular access visualization technologies across neurology, ophthalmology, gastroenterology, and hematology.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Growing — net +6 jobs in 30d
20 jobs added vs 14 removed. Steady team buildout.
Perceptive is a high-risk, early-stage opportunity best suited for mission-driven professionals seeking hands-on roles in imaging innovation, with significant execution and financing risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Perceptive
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Perceptive's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Perceptive (NASDAQ: TRAW) reports 6.1% stake via 979,815 warrants - Stock Titan
Perceptive (NASDAQ: TRAW) reports 6.1% stake via 979,815 warrants Stock Titan
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) - Stock Titan
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) Stock Titan
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A Stock Titan
Perceptive group discloses 6.0% stake in Avalyn Pharma (NASDAQ: AVLN) - Stock Titan
Perceptive group discloses 6.0% stake in Avalyn Pharma (NASDAQ: AVLN) Stock Titan
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors TMX Newsfile
Two biotech investors back Kiora with $5M now, $19M more later - Stock Titan
Two biotech investors back Kiora with $5M now, $19M more later Stock Titan
Showing 6 of 7 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles